pmc logo image
Logo of brjgenpracRCGP homepageJ R Coll Gen Pract at PubMed CentralBJGP at RCGPBJGP at RCGP

Formats:

Br J Gen Pract. 1994 January; 44(378): 30–33.
PMCID: PMC1238759
Detecting patients with Alzheimer's disease suitable for drug treatment: comparison of three methods of assessment.
G K Wilcock, D L Ashworth, J A Langfield, and P M Smith
Department of Care of the Elderly, University of Bristol.
Abstract
BACKGROUND. Therapy to enhance cholinergic function in the brain is under evaluation for the treatment of Alzheimer's disease. Tetrahydroaminoacridine (tacrine) has recently received a product licence in the United States of America for the treatment of Alzheimer's disease, and the licence application in the United Kingdom will shortly be reviewed. It is therefore possible that this drug will become available for use in the UK in due course. There will then be a need for screening procedures for a large number of elderly patients to decide whether or not they have dementia and, if so, whether it is the result of Alzheimer's disease and is suitable for treatment with the new drug. METHOD. A total of 246 patients aged 75 years or over in two general practices in Bristol were assessed to investigate the potential workload such screening would engender. Three different assessment schedules for the diagnosis of dementia were compared--the mini-mental state examination, the Kew test, and the abbreviated mental test score. RESULTS. None of the assessment schedules was found to be particularly onerous, with median times for administration of five, three and two minutes, respectively. A score of 23 or less on the mini-mental state examination was taken as the main cut-off point for further evaluation. Sixty six patients obtained this score--in 25 the low score reflected factors other than dementia, and 11 others declined further assessment. Of the remaining 30 patients only four had probable Alzheimer's disease at an appropriate level of severity for treatment, and lived with a carer who could ensure compliance and monitor side effects. Two of these patients were receiving conflicting medical treatment and a third declined therapy, leaving only one person for whom treatment could be prescribed. CONCLUSION. It seems likely that of those medically suitable for treatment, it may not be possible to prescribe tacrine for an appreciable proportion. Nevertheless, all potential patients should be screened as the procedures involved are not onerous and at least some of those found suitable for treatment are likely to benefit from this new approach.
Full text
Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (895K), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
  • Chatellier G, Lacomblez L. Tacrine (tetrahydroaminoacridine; THA) and lecithin in senile dementia of the Alzheimer type: a multicentre trial. Groupe Français d'Etude de la Tetrahydroaminoacridine. BMJ. 1990 Feb 24;300(6723):495–499. [PubMed]
  • Eagger SA, Levy R, Sahakian BJ. Tacrine in Alzheimer's disease. Lancet. 1991 Apr 27;337(8748):989–992. [PubMed]
  • Davis KL, Thal LJ, Gamzu ER, Davis CS, Woolson RF, Gracon SI, Drachman DA, Schneider LS, Whitehouse PJ, Hoover TM, et al. A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. The Tacrine Collaborative Study Group. N Engl J Med. 1992 Oct 29;327(18):1253–1259. [PubMed]
  • Farlow M, Gracon SI, Hershey LA, Lewis KW, Sadowsky CH, Dolan-Ureno J. A controlled trial of tacrine in Alzheimer's disease. The Tacrine Study Group. JAMA. 1992 Nov 11;268(18):2523–2529. [PubMed]
  • Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975 Nov;12(3):189–198. [PubMed]
  • McDonald C. Clinical heterogeneity in senile dementia. Br J Psychiatry. 1969 Mar;115(520):267–271. [PubMed]
  • Hare M. Clinical check list for diagnosis of dementia. Br Med J. 1978 Jul 22;2(6132):266–267. [PubMed]
  • Hodkinson HM. Evaluation of a mental test score for assessment of mental impairment in the elderly. Age Ageing. 1972 Nov;1(4):233–238. [PubMed]
  • White H, Davis PB. Cognitive screening tests: an aid in the care of elderly outpatients. J Gen Intern Med. 1990 Sep–Oct;5(5):438–445. [PubMed]
  • McDougall GJ. A review of screening instruments for assessing cognition and mental status in older adults. Nurse Pract. 1990 Nov;15(11):18–28. [PubMed]
  • Clarke M, Jagger C, Anderson J, Battcock T, Kelly F, Stern MC. The prevalence of dementia in a total population: a comparison of two screening instruments. Age Ageing. 1991 Nov;20(6):396–403. [PubMed]
  • McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984 Jul;34(7):939–944. [PubMed]
  • Wilcock GK, Hope RA, Brooks DN, Lantos PL, Oppenheimer C, Reynolds GP, Rossor MN, Davies MB. Recommended minimum data to be collected in research studies on Alzheimer's disease. The MRC (UK) Alzheimer's Disease Workshop Steering Committee. J Neurol Neurosurg Psychiatry. 1989 Jun;52(6):693–700. [PubMed]
  • O'Connor DW, Pollitt PA, Hyde JB, Fellows JL, Miller ND, Brook CP, Reiss BB. The reliability and validity of the Mini-Mental State in a British community survey. J Psychiatr Res. 1989;23(1):87–96. [PubMed]